-
The final overall survival (OS) results for 3 major trials in non-metastatic castration-resistant prostate cancer (nmCRPC) were presented: the ARAMIS (darolutamide versus placebo), SPARTAN (apalutamide versus placebo) and PROSPER (enzalutamide versus placebo) trials.
-
The first phase 3 study of pembrolizumab versus standard-of-care demonstrated superiority for first-line pembrolizumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.
-
Older age, poor performance status, and progressing cancer were strongly associated with increased mortality, especially within patient subsets admitted to the ICU and/or that required intubation.
-
In a global registry, 428 thoracic cancer patients infected with COVID-19 have been followed up, and the data are concerning. 169 have recovered, 119 have ongoing COVID-19 infection, but 141 have died.
-
At a 3-years median follow-up, the randomized, phase 3 EORTC 1325/KEYNOTE-054 trial demonstrated that adjuvant pembrolizumab taken for up to 1 year in high-risk stage III melanoma patients improved recurrence-free survival (RFS), with a consistent effect across subgroups.
-
The phase 3 JAVELIN Bladder 100 study showed at its primary endpoint significantly longer overall survival with avelumab first-line maintenance versus control, both in the overall population and the PD-L1+ population, for patients with locally advanced or metastatic urothelial cancer.
-
In patients with platinum-sensitive relapsed ovarian cancer harboring BRCA1/2 mutation, final overall survival (OS) results from the phase 3 SOLO2/ENGOT-ov21 trial showed significant benefit for patients receiving maintenance treatment with olaparib over placebo.
-
Osimertinib demonstrated a significant benefit for patients with stage IB, II, or IIIA EGFR-mutant non-small cell lung cancer with complete tumor resection in the phase 3 ADAURA trial.
-
In patients with newly diagnosed multiple myeloma, carfilzomib with lenalidomide and dexamethasone (KRd) did not improve progression-free survival (PFS), when compared with the current standard of care of bortezomib with lenalidomide and dexamethasone (VRd).
-
Bladder cancer is the sixth most common tumor diagnosis in the EU and up to 70% of tumors develop recurrences within a year. Early detection is a major problem. A new urine test could improve screening.
-
Chemoresistant patients with a gestational trophoblastic tumor (GTT) responded well to avelumab, and 1 patient went on to a normal pregnancy 1 year after treatment, in the first study of its kind.
-
In the times of COVID-19, many rheumatism patients, omit essential drugs for pain control or skip picking up new prescriptions from physicians due to media reports or out of fear. Often, such reactions are completely unfounded.
-
From China to Senegal, from India to Bolivia, no country affected by the virus has been spared the waves of rumors and misinformation that claim miracle cures for a disease that, to date, has no treatment or vaccine.
-
Researchers have developed a new X-ray contrast medium that reaches all blood vessels more reliably and enables precise imaging, helping reduce the number of experimental animals required.
-
Opioid use among European rheumatism sufferers continues to rise, according to recent figures from Catalonia, Spain. The USA opioid crisis comes to mind. Are we sleepwalking into a catastrophe?
-
Researchers are finding another approach to attack therapy-resistant tumors. If the hypoxia-induced factor-1α is switched off in natural killer (NK) cells, tumor growth slows down.
-
A worldwide observational study with 96,000 hospitalized COVID-19 patients showed that those who were treated with hydroxychloroquine or chloroquine had a higher mortality rate and a particularly increased risk of cardiac arrhythmia.
-
A study of the Augsburg University Hospital, Germany, recently showed that the lung tissue of deceased COVID-19 patients is irreversibly damaged.
-
There has not yet been any clear evidence of the brain areas involved in many executive functions involved in behavioral control. A new study has identified this crucial region, with the help of a unique patient and the dysexecutive syndrome.
-
A dominant posture could help children to feel more confident in school. This is the result of a new study that gives first hints on how pupils could feel better at school with simple exercises.
